Scientific Advisory Board
SEKISUI XenoTech has created a Scientific Advisory Board (SAB) of renowned scientists and thought leaders in the pharmaceutical industry.
The board is made up of experts specializing in Absorption, Distribution, Metabolism, and Excretion (ADME) and Drug Metabolism and Pharmacokinetics (DMPK) nonclinical studies, led by Dr. Brian Ogilvie, Vice President of Scientific Consulting for SEKISUI XenoTech.
Dr. Ogilvie sought out thought leaders that have distinctive perspectives on the pharmaceutical industry that have been formulated from their independent expertise and numerous years of experience. Through their insight, SEKISUI XenoTech will be guided to better serve the industry by anticipating growth trends, scientific innovation and ultimately the greater needs of its customers.
I am excited to bring this group together. The combination of our internal knowledge and 25 years of experience in the industry with the infusion of the extensive expertise and well-respected knowledge brought by this SAB will serve to set SEKISUI XenoTech apart as the leader in in vitro DDI and ADME testing services and products.Dr. Brian Ogilvie, VP of Scientific Consulting